Therapy Areas: Oncology
Mirati Therapeutics doses first patient in Phase 1/2 clinical trial of MRTX849
16 January 2019 - Oncology company Mirati Therapeutics Inc (NASDAQ:MRTX) revealed on Tuesday the start of treatment of the first patient under its Phase 1/2 clinical trial of MRTX849 against KRAS G12C...
European Commission Approves Opdivo Plus Low-Dose Yervoy for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
15 January 2019 - - The European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line tr...
US Merck's Keytruda Reduced Risk of Death by 31% Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)
15 January 2019 - - US-based Merck (NYSE: MRK) has made the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating Keytruda, Merck's anti-PD-1 therapy, as monotherapy for t...
US FDA Approves Carbometyx Tablets for Previously Treated Hepatocellular Carcinoma
15 January 2019 - - The US Food and Drug Administration approved Carbometyx (cabozantinib) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib, US-based ...
Leap Therapeutics Launches Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
15 January 2019 - - US-based biotechnology company Leap Therapeutics, Inc. (NASDAQ: LPTX) has launched an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Can...
CytRx Highlights Aldoxorubicin's Inclusion in New NantCell Colorectal Cancer Clinical Trial
15 January 2019 - - US-based biopharmaceutical research and development company CytRx Corp. (NASDAQ: CYTR) has highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of...